 Aziridines
"Aziridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Saturated azacyclopropane compounds. They include compounds with substitutions on CARBON or NITROGEN atoms.
| Descriptor ID |
D001388
|
| MeSH Number(s) |
D03.383.097.217
|
| Concept/Terms |
Aziridines- Aziridines
- Ethyleneimines
- Azacyclopropanes, Saturated
- Saturated Azacyclopropanes
- Dimethyleneimines
|
Below are MeSH descriptors whose meaning is more general than "Aziridines".
Below are MeSH descriptors whose meaning is more specific than "Aziridines".
This graph shows the total number of publications written about "Aziridines" by people in this website by year, and whether "Aziridines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Aziridines" by people in Profiles.
-
Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). Mol Pharmacol. 2008 Dec; 74(6):1657-65.
-
Dehn DL, Inayat-Hussain SH, Ross D. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis. J Pharmacol Exp Ther. 2005 May; 313(2):771-9.
-
Dehn DL, Winski SL, Ross D. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1. Clin Cancer Res. 2004 May 01; 10(9):3147-55.
-
Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, Ross D. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol. 2001 Jun 15; 61(12):1509-16.
-
Winski SL, Hargreaves RH, Butler J, Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res. 1998 Dec; 4(12):3083-8.
-
Ross D, Beall HD, Siegel D, Traver RD, Gustafson DL. Enzymology of bioreductive drug activation. Br J Cancer Suppl. 1996 Jul; 27:S1-8.
-
Archibald YM, Lunn D, Ruttan LA, Macdonald DR, Del Maestro RF, Barr HW, Pexman JH, Fisher BJ, Gaspar LE, Cairncross JG. Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg. 1994 Feb; 80(2):247-53.
-
Halperin EC, Gaspar L, Imperato J, Salter M, Herndon J, Dowling S. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium. Am J Clin Oncol. 1993 Aug; 16(4):277-83.
-
Gibson NW, Hartley JA, Butler J, Siegel D, Ross D. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. Mol Pharmacol. 1992 Sep; 42(3):531-6.
-
Lee CS, Hartley JA, Berardini MD, Butler J, Siegel D, Ross D, Gibson NW. Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase. Biochemistry. 1992 Mar 24; 31(11):3019-25.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|